Clinical Trial Update: Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting the safety data of 32P BioSilicon in patients with hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• 32P BioSilicon (32P-labeled BioSilicon compound)

Snippet

Sponsor: pSiVida Limited | Conditions: Liver Cancer | Phase 2 | Status: UNKNOWN